Companies
Immunocore
Kimmtrak (tebentafusp), a soluble gp100 TCR-anti-CD3 bispecific for HLA-A02:01+ metastatic uveal melanoma, was reported in April 2026 to double the likelihood of being alive at five years — the first TCR-based bispecific approved.
- Country
- United Kingdom
- Ticker
- IMCR
Commercial
TCR bispecific (Kimmtrak)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $864 million in cash and cash equivalents as of year-end 2025 | immunocore.com |
| Capacity | outsourced to third-party contract manufacturing organizations (CMOs); company does not own or plan to build its own manufacturing capacity | nullexposure.com |
| Production site | Denmark, Germany, and the Netherlands (final packaging) | immunocore.com · nullexposure.com |
| Headcount | 524 full-time employees as of December 31, 2025 | longbridge.com |
| Revenue | $400 million in net revenue for the fiscal year 2025 | immunocore.com |
| Revenue | $106.7 million in net product revenue for the first quarter of 2026 | immunocore.com |
| Regulatory approval | KIMMTRAK approved for metastatic uveal melanoma in 39 countries, including the United States, European Union, United Kingdom, Canada, and Australia | immunocore.com |
Independent sources: longbridge.com · nullexposure.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| TCR therapy (T-cell receptor engineered T cells) | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.